Structural Determinants Shaping Modern GLP‑1 Analog Therapeutics

GLP‑1 analogs rely on structural features that enhance stability, receptor affinity, and half‑life. N‑terminal protection, C‑terminal and backbone stabilization, and lipidation drive potency and duration, while structural variation shapes signaling bias. Multi‑receptor agonists and computational design now guide next‑generation incretin therapies.


Read full article for free (open access):

https://www.sciencedirect.com/science/article/pii/S2319417026000934


GLP-1R binding and activation through a multi-step process. GLP1 obesity


Popular posts from this blog

Salivary microbiome diversity is associated with oral health and disease

Pacific has one of most successful years for grants in school history